Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NXTC

Nextcure Inc

Sep 15 • 04:00PM ET

5.50

+0.10 1.93 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT ALLO FOLD XNCR ANAB IGMS NKTR ONCT ACHV ANGO

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-25.91	Insider Own	45.86%	Shs Outstand	2.34M	Perf Week	11.79%
Market Cap	14.74M	Forward P/E	-	EPS next Y	-12.08	Insider Trans	0.00%	Shs Float	1.45M	Perf Month	6.84%
Enterprise Value	-15.27M	PEG	-	EPS next Q	-3.98	Inst Own	24.23%	Short Float	2.74%	Perf Quarter	-32.70%
Income	-60.93M	P/S	-	EPS this Y	16.16%	Inst Trans	-45.99%	Short Ratio	0.34	Perf Half Y	-33.47%
Sales	0.00M	P/B	0.41	EPS next Y	39.66%	ROA	-81.09%	Short Interest	0.04M	Perf YTD	-40.55%
Book/sh	13.54	P/C	0.42	EPS next 5Y	68.03%	ROE	-104.07%	52W High	19.20 -71.35%	Perf Year	-66.05%
Cash/sh	13.18	P/FCF	-	EPS past 3/5Y	7.48% 1.53%	ROIC	-167.79%	52W Low	2.69 104.61%	Perf 3Y	-87.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.09% 5.33%	Perf 5Y	-94.68%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	1.66%	Oper. Margin	-	ATR (14)	0.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.71	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.51	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	3.71	EPS Q/Q	-70.83%	SMA20	6.73%	Beta	1.31	Target Price	17.50
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	7.08%	Rel Volume	0.15	Prev Close	5.40
Employees	43	LT Debt/Eq	0.15	Earnings	Aug 07 AMC	SMA200	-23.79%	Avg Volume	118.38K	Price	5.50
IPO	May 09, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	-144.64% -	Trades		Volume	18,296	Change	1.93%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-22	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-22	Initiated	Ladenburg Thalmann	Buy	$16
Mar-05-21	Upgrade	Truist	Hold → Buy	$19
Jan-15-21	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-16-20	Upgrade	The Benchmark Company	Hold → Buy	$17
Jul-13-20	Downgrade	SunTrust	Buy → Hold
Jul-13-20	Downgrade	ROTH Capital	Buy → Neutral
Jun-01-20	Downgrade	The Benchmark Company	Buy → Hold
Jun-01-20	Downgrade	BofA/Merrill	Buy → Neutral	$62 → $40
May-26-20	Initiated	JMP Securities	Mkt Outperform	$55
Mar-24-20	Initiated	The Benchmark Company	Buy	$55
Mar-02-20	Initiated	ROTH Capital	Buy	$80
Jan-13-20	Initiated	SunTrust	Buy	$78
Dec-05-19	Initiated	Needham	Buy
Nov-26-19	Initiated	BTIG Research	Buy	$61
Jul-09-19	Initiated	BofA/Merrill	Buy	$25
Jun-03-19	Initiated	Piper Jaffray	Overweight	$26
Jun-03-19	Initiated	Morgan Stanley	Overweight	$25

Show Previous Ratings

Sep-04-25 07:00AM	NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-07-25 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-24-25 04:05PM	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta (GlobeNewswire) +17.30%
Jun-17-25 05:34AM	NextCure and Simcere partner to develop SIM0505 for solid tumours (Pharmaceutical Technology) -10.08%
Jun-16-25 07:05AM	NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 (GlobeNewswire) -26.27%
11:03PM	Loading…
May-29-25 11:03PM	NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 (Insider Monkey) +6.41%
04:05PM	NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 (GlobeNewswire)
May-01-25 04:05PM	NextCure Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -7.81%
Apr-04-25 07:00AM	NextCure to Present at 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-06-25 04:05PM	NextCure Provides Business Update and Reports Full Year 2024 Financial Results (GlobeNewswire) +5.20%
Jan-10-25 08:05AM	NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers (GlobeNewswire) -6.11%
Dec-10-24 08:05AM	NextCure Announces Acceptance of IND Application for LNCB74 (GlobeNewswire)
Nov-26-24 07:00AM	NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-19-24 08:05AM	Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta (GlobeNewswire)
Nov-08-24 06:18AM	NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space (FierceBiotech.com)
04:05PM	Loading…
Nov-07-24 04:05PM	NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 04:05PM	NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Oct-04-24 09:05AM	NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-16-24 08:05AM	NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 (GlobeNewswire)
Aug-01-24 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-20-24 04:10PM	NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire) +13.64% +8.00%
May-30-24 04:05PM	NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 (GlobeNewswire)
May-02-24 09:57PM	NXTC Stock Earnings: NextCure Misses EPS for Q1 2024 (InvestorPlace) +8.76%
04:05PM	NextCure Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:05PM	NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire) -5.88% -10.42%
Apr-08-24 07:00AM	NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 (GlobeNewswire) -5.96%
Apr-04-24 07:05AM	NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board (GlobeNewswire) -10.00%
Apr-02-24 07:00AM	NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +7.79%
Mar-23-24 06:00AM	Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-21-24 10:54PM	NXTC Stock Earnings: NextCure Beats EPS for Q4 2023 (InvestorPlace) +19.15% +13.10%
11:22AM	Loading…
11:22AM	NextCure to lay off 37% of staff, dial back research plans (BioPharma Dive)
08:55AM	NextCure Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 08:05AM	NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances (GlobeNewswire)
Jan-18-24 04:05PM	NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders (GlobeNewswire)
Dec-25-23 09:55AM	Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing (Zacks)
Dec-21-23 07:05AM	NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury (GlobeNewswire)
Dec-15-23 11:23AM	NextCure (NXTC) Down on Shelving Plans to Develop Candidate (Zacks) -5.13%
Dec-14-23 09:14AM	NextCure jettisons monoclonal antibody to focus on ADC aimed at same target (FierceBiotech.com) -19.31%
06:45AM	NextCure Provides Year-End Clinical Pipeline Updates (GlobeNewswire)
Nov-20-23 07:00AM	NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-15-23 04:05PM	NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML (GlobeNewswire) +5.93% -6.40%
Nov-07-23 12:00PM	All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy (Zacks)
Nov-02-23 06:07PM	NextCure Inc (NXTC) Reports Q3 2023 Financial Results (GuruFocus.com) +9.35%
04:05PM	NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-17-23 08:05AM	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-26-23 04:05PM	NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimers Disease (GlobeNewswire)
Sep-12-23 08:05AM	A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC (GlobeNewswire)
Sep-07-23 04:05PM	NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen (GlobeNewswire)
Sep-05-23 04:05PM	Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease (GlobeNewswire)
Aug-31-23 07:00AM	NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-21-23 04:05PM	NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting (GlobeNewswire)
May-11-23 01:58PM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
May-09-23 07:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire) +7.41%
May-04-23 04:05PM	NextCure Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-11-23 07:00AM	NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-02-23 04:05PM	NextCure Provides Business Update and Reports Full Year 2022 Financial Results (GlobeNewswire)
Feb-07-23 07:00AM	NextCure to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-02-22 10:59AM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-22-22 08:00AM	NextCure to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-16-22 08:09AM	NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates (Benzinga) -6.02%
Nov-15-22 04:30PM	NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates (GlobeNewswire)
Nov-07-22 08:05AM	NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) -13.64%
Nov-03-22 04:15PM	NextCure Provides Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -21.12%
09:15AM	NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-27-22 04:05PM	NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board (GlobeNewswire)
Oct-05-22 12:00PM	NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
08:15AM	NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Oct-04-22 04:05PM	NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors (GlobeNewswire) +9.42%
Sep-22-22 08:00AM	NextCure to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire) -12.64%
Aug-22-22 06:23AM	With 37% ownership, NextCure, Inc. (NASDAQ:NXTC) has piqued the interest of institutional investors (Simply Wall St.) -5.45%
Aug-04-22 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) +6.32%
Jul-06-22 08:00AM	NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation (GlobeNewswire)
Jun-27-22 08:00AM	NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM (GlobeNewswire)
Jun-25-22 10:26AM	We're Hopeful That NextCure (NASDAQ:NXTC) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-22 08:00AM	Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting (GlobeNewswire)
Jun-08-22 08:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-11-22 08:17AM	NextCure, Inc.'s (NASDAQ:NXTC) Intrinsic Value Is Potentially 34% Above Its Share Price (Simply Wall St.)
May-05-22 04:05PM	NextCure Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-03-22 08:00AM	NextCure to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-19-22 07:30AM	NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation (GlobeNewswire)
Apr-05-22 08:00AM	NextCure to Present at 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-15-22 06:21AM	What Type Of Shareholders Own The Most Number of NextCure, Inc. (NASDAQ:NXTC) Shares? (Simply Wall St.)
Mar-03-22 04:05PM	NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-08-22 08:00AM	NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Dec-13-21 08:05AM	NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-30-21 08:00AM	NextCure to Present at The JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-22-21 08:00AM	NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-13-21 02:00PM	NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Nov-04-21 04:05PM	NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
09:15AM	NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-01-21 08:00AM	NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021 (GlobeNewswire)
Oct-19-21 08:05AM	NextCure Announces Three New Members of its Scientific Advisory Board (GlobeNewswire)
Oct-07-21 04:05PM	NextCure Announces Publication of Preclinical Data for NC410 (GlobeNewswire)
Oct-04-21 08:05AM	NextCure Announces New Appointments to its Board of Directors (GlobeNewswire)
Oct-01-21 08:45AM	NextCure to Give Three Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +12.17%
Sep-29-21 10:41AM	What Is The Ownership Structure Like For NextCure, Inc. (NASDAQ:NXTC)? (Simply Wall St.)
Sep-07-21 07:00AM	NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-02-21 07:00AM	NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-05-21 04:05PM	NextCure Reports Second Quarter 2021 Financial Results (GlobeNewswire)

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NXTC

Nextcure Inc

Upgrade your FINVIZ experience